Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15023129 | 0.82 | KIF11 (0.46) | PLA2G7GAAIDO1 | |
| SCHEMBL3181345 | 0.82 | IDO1 (0.45) | CA2NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3176520 | 0.82 | KCNA3 (0.39) | PLA2G7ALDH1A1KMT2AIDO1 | |
| SCHEMBL8153637 | 0.82 | PTGS2 (0.53) | PLA2G7CES2CES1NFE2L2PTGS2 | |
| SCHEMBL7621027 | 0.82 | PTGS2 (0.53) | PLA2G7CES2CES1NFE2L2PTGS2 | |
| SCHEMBL3182714 | 0.79 | KIF11 (0.51) | CES2KCNN4 | |
| SCHEMBL2400367 | 0.79 | NR3C2 (0.41) | — | |
| SCHEMBL16649614 | 0.77 | CYP11B2 (0.47) | TRPA1 | |
| SCHEMBL16649771 | 0.77 | CES2 (0.46) | PLA2G7CES2CES1CA12CA1 | |
| SCHEMBL16649745 | 0.76 | PLA2G7 (0.44) | PLA2G7CES2CES1NFE2L2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133718-A1 | PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-05-05 | — | — | US | claimed |
| US-20200390764-A1 | PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE | VIRACTA THERAPEUTICS, INC. | 2020-12-17 | — | — | US | claimed |
| US-20190175589-A1 | PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE | SUNESIS PHARMACEUTICALS, INC. | 2019-06-13 | — | — | US | claimed |
| US-20240207258-A1 | HETEROCYCLIC PDK1 INHIBITORS FOR USE TO TREAT CANCER | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-06-27 | — | — | US | disclosed |
| EP-3466929-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230113598-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | BIOGEN IDEC MA INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230099829-A1 | HETEROCYCLIC PDK1 INHIBITORS FOR USE TO TREAT CANCER | VIRACTA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20220133718-A1 | PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-05-05 | — | — | US | disclosed |
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2021-03-11 | — | — | US | disclosed |
| EP-3763368-A1 | HETEROCYCLIC PDK1 INHIBITORS FOR USE TO TREAT CANCER | Sunesis Pharmaceuticals, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200390764-A1 | PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE | VIRACTA THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| EP-3070077-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9546165-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-11-17 | — | — | US | disclosed |
| EP-3070077-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2485731-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-2121617-B1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA AS (DK) | 2014-01-22 | — | — | EP | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | PLA2G7 1285/4885CES2 3357/4885CES1 1238/4885 |
| US-20190175589-A1 | PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE | PRKCA, PIK3CA, AKT2 | PLA2G7 549/4885CES2 3507/4885CES1 2587/4885 |
| US-20220133718-A1 | PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE | PRKCA, PIK3CA, AKT2 | PLA2G7 549/4885CES2 3507/4885CES1 2587/4885 |
| US-20200390764-A1 | PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE | PRKCA, PIK3CA, AKT2 | PLA2G7 549/4885CES2 3507/4885CES1 2587/4885 |
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | PLA2G7 1285/4885CES2 3357/4885CES1 1238/4885 |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | CNR1, CNR2, GPR6 | PLA2G7 1647/4885CES2 500/4885CES1 312/4885 |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | PDK1, PDK2, PDK3 | PLA2G7 1285/4885CES2 3357/4885CES1 1238/4885 |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | PLA2G7 1285/4885CES2 3357/4885CES1 1238/4885 |
| US-20230099829-A1 | HETEROCYCLIC PDK1 INHIBITORS FOR USE TO TREAT CANCER | PDK1, PDK2, PDK3 | PLA2G7 2657/4885CES2 3808/4885CES1 2128/4885 |
| US-20230113598-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | PLA2G7 1285/4885CES2 3357/4885CES1 1238/4885 |
| US-20240207258-A1 | HETEROCYCLIC PDK1 INHIBITORS FOR USE TO TREAT CANCER | PDK1, PDK2, PDK3 | PLA2G7 2657/4885CES2 3808/4885CES1 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.